Primaquine Loaded Solid Lipid Nanoparticles (SLN), Nanostructured Lipid Carriers (NLC), and Nanoemulsion (NE): Effect of Lipid Matrix and Surfactant on Drug Entrapment, in vitro Release, and ex vivo Hemolysis
- 29 September 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in AAPS PharmSciTech
- Vol. 22 (7), 1-12
- https://doi.org/10.1208/s12249-021-02108-5
Abstract
Primaquine (PQ), an 8-aminoquinoline antimalarial drug, has been widely used for the eradication of hypnozoites from the liver and, therefore, recognized as the radical cure of malaria. However, the clinical applications of PQ are restricted to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to severe dose-related hemolytic side effects. Nanoparticle carriers have shown great potential in achieving higher PQ concentrations in the target site, thereby reducing dose-related systemic toxicity caused by non-specific exposure. This work aims to develop, compare, and evaluate three PQ-loaded lipid-based drug carriers including solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and nano-emulsions (NE). The optimized PQ-SLN, PQ-NLC, and PQ-NE had a particle size of 250 nm, a PDI range of 0.1 to 0.3, a zeta potential of − 30 mV, and entrapment efficiency of ~ 90%. All lipid formulations showed sustained release in both simulated gastric and intestinal fluids over 6 h. Four empirical models — including zero-order, Higuchi, Korsmeyer-Peppas, and Hixson-Crowell models — were tested to understand the drug release mechanisms of PQ-SLN, PQ-NLC, and PQ-NE. The model fitness was found to be the highest in the Korsmeyer-Peppas model for all the PQ-loaded lipid formulations (R2: 0.88–0.94). No significant changes were observed in the entrapment efficiency, particle size, and PDI of lipid formulations throughout 1 month of storage at 4 °C and 25 °C. PQ-SLN and PQ-NLC can be further lyophilized with cryoprotectants to improve long-term stability. Finally, the treatment of erythrocytes with PQ-SLN, PQ-NLC, and PQ-NE reduced erythrocyte hemolysis by approximately 4.5-fold compared to the free drug solution. Graphical abstractKeywords
This publication has 32 references indexed in Scilit:
- Primaquine in vivax malaria: an update and review on management issuesMalaria Journal, 2011
- Preparation, Characterization, Pharmacokinetics and Tissue Distribution of Solid Lipid Nanoparticles Loaded with TetrandrineAAPS PharmSciTech, 2011
- Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug DeliveryAAPS PharmSciTech, 2010
- Nanoemulsion Components Screening and Selection: a Technical NoteAAPS PharmSciTech, 2009
- Oral lipid-based formulationsAdvanced Drug Delivery Reviews, 2007
- Targeting primaquine into liver using chylomicron emulsions for potential vivax malaria therapyInternational Journal of Pharmaceutics, 2005
- Can primaquine therapy for vivax malaria be improved?Trends in Parasitology, 2003
- Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the artEuropean Journal of Pharmaceutics and Biopharmaceutics, 2000
- Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN)International Journal of Pharmaceutics, 1997
- A simple equation for description of solute release II. Fickian and anomalous release from swellable devicesJournal of Controlled Release, 1987